The goal of this study is to evaluate the efficacy and safety of r-h(alpha)GAL compared to placebo in reducing GL-3 accumulation in involved organs in patients with Fabry Disease. Also, to evaluate these patients with regard to the improvement in pain and quality of life.
Showing the most recent 10 out of 642 publications